Psoriatic Arthritis Therapeutics Market to Reach USD 25.18 Billion by 2033 at 8.5% CAGR; North America Leads with 41.2% Share - Key Players: AbbVie, Novartis, Janssen Biotech

The global psoriatic arthritis therapeutics market was valued at USD 14.8 billion in 2025 and is projected to reach nearly USD 25.18 billion by 2033, growing at a CAGR of 8.5% during the forecast period from 2026 to 2033. The market is witnessing strong growth driven by the increasing prevalence of autoimmune and inflammatory disorders, rising awareness regarding early diagnosis of psoriatic arthritis, and growing demand for targeted biologic therapies worldwide. Expanding adoption of TNF inhibitors, interleukin inhibitors, JAK inhibitors, and disease modifying anti rheumatic drugs (DMARDs) is significantly improving disease management and patient outcomes across healthcare systems. In addition, advancements in precision medicine, biomarker based diagnostics, and personalized immunotherapy approaches are accelerating market expansion globally.

The market is also benefiting from continuous regulatory approvals, expanding reimbursement support, and increasing investments in autoimmune disease research by pharmaceutical companies. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) continue to support development of innovative psoriatic arthritis therapies through fast track approvals and updated rheumatology treatment guidelines. Companies including AbbVie Inc., Novartis AG, Johnson & Johnson, and Amgen Inc. are actively focusing on next generation biologics, oral targeted therapies, and expanded immunology treatment portfolios to strengthen their market presence. Furthermore, increasing clinical trial activity for novel cytokine inhibitors and growing adoption of combination therapy approaches are creating substantial growth opportunities for the psoriatic arthritis therapeutics market worldwide.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/psoriatic-arthritis-therapeutics-market?sai-v

Key Developments
February 2026: Rising adoption of biologics, targeted immunotherapies, and AI-enabled disease monitoring accelerated growth in the psoriatic arthritis therapeutics market across North America and Europe. Major companies including AbbVie Inc., Johnson & Johnson, Pfizer Inc., and Novartis AG expanded innovation in IL-17 and TNF inhibitor therapies.

January 2026: Increasing prevalence of autoimmune disorders and expanding healthcare access across the United States, Germany, Japan, China, and India strengthened demand for advanced psoriatic arthritis treatment solutions. Asia-Pacific emerged as the fastest growing regional market driven by improving diagnosis rates and healthcare investments.

December 2025: Growing adoption of biologic therapies and oral small molecule drugs improved long-term disease management for psoriatic arthritis patients globally. Pharmaceutical companies strengthened development of next generation JAK inhibitors and precision immunology treatments.

November 2025: Expansion of rheumatology specialty clinics and digital healthcare platforms across Europe and North America improved accessibility to psoriatic arthritis diagnosis and treatment services. Healthcare providers increasingly integrated remote patient monitoring and tele-rheumatology solutions.

October 2025: Rising advancements in biomarker-based diagnostics, personalized medicine, and regenerative immunology improved treatment precision and patient outcome monitoring globally. Research institutions accelerated innovation in targeted autoimmune disease therapies.

September 2025: Increasing collaborations between pharmaceutical companies, biotechnology firms, and research organizations accelerated clinical trials evaluating advanced biologics and combination therapies for psoriatic arthritis worldwide. Europe and Asia-Pacific strengthened investments in autoimmune disease research infrastructure.

August 2025: Growing healthcare investments and awareness regarding inflammatory arthritis disorders improved accessibility to psoriatic arthritis therapeutics across Middle East, Latin America, and Asia-Pacific regions. Governments expanded reimbursement support for biologic and specialty therapies.

July 2025: Rising demand for home-based injectable therapies and digital disease management platforms improved long-term patient adherence and treatment monitoring globally. Companies including Amgen Inc. and UCB Pharma strengthened innovation in patient-centric autoimmune care solutions.

June 2025: Increasing focus on precision immunology, early diagnosis, and advanced biologic therapies supported strong growth in the psoriatic arthritis therapeutics market worldwide. North America maintained market leadership due to advanced healthcare infrastructure, while Asia-Pacific recorded rapid growth driven by rising autoimmune disease awareness and healthcare modernization initiatives.

Key Players
AbbVie, Inc. | Janssen Biotech, Inc. | Novartis AG | Amgen, Inc. | Celgene Corporation | Pfizer, Inc. | Eli Lilly and Company | UCB, Inc. | Biogen Inc. | Bristol-Myers Squibb Company | Others

Key Highlights
AbbVie, Inc. - Holds a 16.8% share, driven by blockbuster immunology therapies, strong biologics portfolio, and extensive research in autoimmune and inflammatory disease treatments.

Janssen Biotech, Inc. - Holds a 14.2% share, supported by advanced monoclonal antibody therapies, innovative immunology drug development, and strong global pharmaceutical commercialization capabilities.

Novartis AG - Holds a 12.0% share, fueled by targeted biologic treatment innovation, advanced autoimmune disease research programs, and expanding specialty pharmaceutical infrastructure.

Amgen, Inc. - Holds a 10.3% share, driven by biologics manufacturing expertise, innovative inflammatory disease therapeutics, and strong investments in precision medicine technologies.

Celgene Corporation - Holds an 8.7% share, supported by immunomodulatory drug development capabilities, specialty treatment innovation, and strong oncology and immunology research expertise.

Pfizer, Inc. - Holds a 7.1% share, powered by diversified pharmaceutical portfolio, advanced immunology R&D programs, and broad international healthcare distribution networks.

Eli Lilly and Company - Holds a 6.0% share, driven by innovative autoimmune disease therapies, biologics development capabilities, and expanding specialty medicine commercialization infrastructure.

UCB, Inc. - Holds a 4.9% share, supported by strong immunology and neurology treatment portfolio, advanced biologic research technologies, and global specialty healthcare capabilities.

Biogen Inc. - Holds a 3.8% share, fueled by advanced biologic therapies, neuroscience and immunology expertise, and strong investments in chronic inflammatory disease research.

Bristol-Myers Squibb Company - Holds a 2.9% share, driven by immunotherapy innovation, precision medicine capabilities, and extensive global pharmaceutical research infrastructure.

Others - Hold a combined 13.3% share, comprising regional biologics manufacturers, specialty pharmaceutical firms, and emerging biotechnology companies advancing autoimmune and inflammatory disease treatment solutions globally.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=psoriatic-arthritis-therapeutics-market?sai-v

Market Drivers

Increasing prevalence of psoriatic arthritis and rising incidence of autoimmune and inflammatory disorders are significantly driving demand for psoriatic arthritis therapeutics globally.

Growing adoption of biologics, biosimilars, targeted therapies, and immunomodulators is accelerating expansion of the psoriatic arthritis therapeutics market worldwide.

Rising awareness regarding early diagnosis and long-term disease management is strengthening utilization of advanced rheumatology treatment solutions across healthcare systems.

Increasing investments in precision medicine, monoclonal antibodies, and cytokine-targeted therapies are supporting continuous innovation in psoriatic arthritis treatment development.

Expansion of healthcare infrastructure, specialty rheumatology clinics, and access to advanced diagnostic technologies is improving patient access to psoriatic arthritis therapies globally.

Continuous advancements in IL-17 inhibitors, TNF inhibitors, JAK inhibitors, and oral small-molecule therapies are enhancing treatment efficacy and patient outcomes.

Growing healthcare expenditure, favorable reimbursement frameworks, and increasing government support for autoimmune disease management are further propelling market development worldwide.

Industry Developments

Rapid advancement in biologic therapies and next-generation monoclonal antibodies improving symptom control and long-term disease remission in psoriatic arthritis patients.

Increasing adoption of biosimilars and targeted oral therapies enhancing treatment affordability, accessibility, and patient adherence.

Growing investments in precision immunology, biomarker-based therapeutics, and personalized medicine approaches supporting innovation in autoimmune disease management.

Expansion of clinical trials evaluating combination therapies, dual-action biologics, and novel cytokine inhibitors accelerating development of advanced psoriatic arthritis treatments.

Rising collaborations among pharmaceutical companies, biotechnology firms, rheumatology research institutes, and healthcare providers driving innovation in inflammatory disease therapeutics.

Strategic regulatory approvals and product launches for advanced biologics and oral immunotherapies supporting global commercialization of psoriatic arthritis treatments.

Continuous innovation in digital disease monitoring platforms, AI-assisted rheumatology diagnostics, and remote patient management systems improving long-term patient care and treatment optimization.

Regional Insights

North America 41.2% share: "Leads the market due to advanced healthcare infrastructure, high adoption of biologics and targeted therapies, strong rheumatology research ecosystem, and increasing autoimmune disease prevalence."

Europe 29.1% share: "Growth supported by expanding access to advanced biologics, favorable reimbursement systems, increasing awareness regarding autoimmune disorders, and rising investments in immunology research."

Asia Pacific 22.8% share: "Fastest-growing region driven by improving healthcare infrastructure, rising autoimmune disease diagnosis rates, increasing healthcare expenditure, and expanding pharmaceutical investments in countries such as China, India, Japan, and South Korea."

Latin America 4.0% share: "Emerging growth supported by improving access to rheumatology care services, increasing adoption of biologic therapies, and gradual healthcare modernization initiatives."

Middle East & Africa 2.9% share: "Gradual growth driven by expanding healthcare infrastructure, rising awareness regarding autoimmune disease management, and improving access to advanced rheumatology treatments."

Speak to our analyst and get customization in the report as per your requirements:https://www.datamintelligence.com/customize/psoriatic-arthritis-therapeutics-market?sai-v

Key Segments
➥ By Drug Class

Nonsteroidal Anti-Inflammatory Drug (NSAID): Represents the dominant segment, driven by widespread use for pain relief, inflammation reduction, and symptomatic management of psoriatic arthritis.

Disease-Modifying Antirheumatic Drug (DMARD) (Antimalarials, Corticosteroids): Represents a significant segment, supported by increasing adoption for slowing disease progression and reducing joint damage in autoimmune arthritis patients.

Biologic Drugs (TNF-alpha, IL-inhibitors, T cell inhibitors): Represents a rapidly growing segment, fueled by rising demand for targeted therapies with improved efficacy in moderate to severe psoriatic arthritis treatment.

➥ By Route of Administration

Oral: Represents the dominant segment, driven by high patient preference, convenience of administration, and extensive use of NSAIDs and conventional DMARD therapies.

Parenteral: Represents a rapidly growing segment, supported by increasing utilization of injectable biologic therapies and advanced immunomodulatory treatments.

Topical: Represents a significant segment, fueled by growing use of localized therapies for managing skin lesions and mild inflammatory symptoms associated with psoriatic arthritis.

➥ By Distribution Channel

Hospital Pharmacies: Represents the dominant segment, driven by high prescription volume of biologics, specialty medications, and hospital-based autoimmune disease management services.

Retail Pharmacies: Represents a significant segment, supported by widespread accessibility of oral medications and long-term outpatient treatment prescriptions.

Online Pharmacies: Represents a rapidly growing segment, fueled by increasing digital healthcare adoption, home delivery services, and growing patient preference for convenient medication purchasing platforms.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.